Repurposing as a strategy for the discovery of new anti-leishmanials: the-state-of-the-art.
Repurposing as a strategy for the discovery of new anti-leishmanials: the-state-of-the-art.
复制标题
DOI：
10.1017/s0031182017000993
复制
发表时间：
2018-03
期刊：
影响因子：
2.4
通讯作者：
Steel PG
中科院分区：
文献类型：
--
作者：
Charlton RL;Rossi-Bergmann B;Denny PW;Steel PG
利什曼病是一种媒介传播的被忽视的热带疾病，由利什曼原虫属的原生动物寄生虫引起，缺乏有效可行的无毒药物。每年有130万新病例造成相当大的社会经济困难，最好的衡量标准是240万残疾调整生命年，对最贫困社区的影响最大，这意味着迫切需要的新的抗利什曼病治疗必须既负担得起又容易获得。具有更便宜和更快开发时间的成熟药物可能会治愈这种被忽视的热带疾病。这种用旧药物治疗新疾病的概念可能并不新颖，但鉴于到2020年控制或根除热带疾病的宏伟目标，这一战略仍然是一项重要战略。在这篇综述中，我们将探讨目前最先进的药物再利用策略，在寻找新的治疗利什曼病。
Leishmaniasis is a vector-borne neglected tropical disease caused by protozoan parasites of the genus Leishmania for which there is a paucity of effective viable non-toxic drugs. There are 1·3 million new cases each year causing considerable socio-economic hardship, best measured in 2·4 million disability adjusted life years, with greatest impact on the poorest communities, which means that desperately needed new antileishmanial treatments have to be both affordable and accessible. Established medicines with cheaper and faster development times may hold the cure for this neglected tropical disease. This concept of using old drugs for new diseases may not be novel but, with the ambitious target of controlling or eradicating tropical diseases by 2020, this strategy is still an important one. In this review, we will explore the current state-of-the-art of drug repurposing strategies in the search for new treatments for leishmaniasis.